SAB Biotherapeutics (SABS)
3.38
-0.09 (2.59%)
Upcoming Events
Latest Headlines
Citi Starts SAB Biotherapeutics (SABS) at Buy
May 22, 2026 5:08 AM - StreetInsider
Jefferies Starts SAB Biotherapeutics (SABS) at Buy
May 20, 2026 3:18 AM - StreetInsider
Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: PERCEPTIVE ADVISORS LLC
May 15, 2026 4:00 PM - SEC Filing
Form SCHEDULE 13G SAB Biotherapeutics, Filed by: Caligan Partners LP
May 15, 2026 11:18 AM - SEC Filing
Form SCHEDULE 13G SAB Biotherapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
May 15, 2026 6:36 AM - SEC Filing
SAB Biotherapeutics (SABS) PT Raised to $10 at H.C. Wainwright
May 12, 2026 12:07 PM - StreetInsider
Form 10-Q SAB Biotherapeutics, For: Mar 31
May 12, 2026 7:36 AM - SEC Filing
SAB Biotherapeutics reports Q1 2026 results, enrollment progress
May 12, 2026 7:30 AM - StreetInsider
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
May 12, 2026 7:30 AM - Globe NewsWire
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
May 5, 2026 8:30 AM - Globe NewsWire
Form 8-K SAB Biotherapeutics, For: Apr 28
May 4, 2026 4:36 PM - SEC Filing
Form SCHEDULE 13G SAB Biotherapeutics, Filed by: MILLENNIUM MANAGEMENT LLC
May 1, 2026 4:57 PM - SEC Filing
Form DEF 14A SAB Biotherapeutics, For: Jun 18
April 30, 2026 4:45 PM - SEC Filing
Emergent BioSolutions signs $50 million manufacturing deal with SAB BIO
April 29, 2026 7:35 AM - StreetInsider
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
April 29, 2026 7:35 AM - Globe NewsWire
Form 8-K SAB Biotherapeutics, For: Apr 22
April 22, 2026 8:14 AM - SEC Filing
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
April 15, 2026 8:01 AM - Globe NewsWire
Rodman & Renshaw Starts SAB Biotherapeutics (SABS) at Buy
April 2, 2026 6:31 AM - StreetInsider
Form S-8 SAB Biotherapeutics,
March 31, 2026 5:36 PM - SEC Filing
Form 4 SAB Biotherapeutics, For: Mar 24 Filed by: Kropotova Alexandra
March 25, 2026 4:35 PM - SEC Filing
Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
March 23, 2026 4:26 PM - SEC Filing
Form 8-K SAB Biotherapeutics, For: Mar 17
March 19, 2026 6:05 AM - SEC Filing
Form 424B5 SAB Biotherapeutics,
March 19, 2026 6:04 AM - SEC Filing
SAB Biotherapeutics prices $85 million public offering at $3.85 per share
March 17, 2026 10:46 PM - StreetInsider
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
March 17, 2026 10:46 PM - Globe NewsWire
Form 424B5 SAB Biotherapeutics,
March 17, 2026 4:01 PM - SEC Filing
Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
March 11, 2026 4:43 PM - SEC Filing
SAB Biotherapeutics (SABS) PT Raised to $6 at Craig-Hallum
March 11, 2026 9:00 AM - StreetInsider
SAB Biotherapeutics (SABS) PT Lowered to $7 at H.C. Wainwright
March 11, 2026 6:57 AM - StreetInsider
Form 8-K SAB Biotherapeutics, For: Mar 10
March 10, 2026 7:37 AM - SEC Filing
SAB BIO reports Phase 1 data showing C-peptide preservation signals
March 10, 2026 7:31 AM - StreetInsider
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
March 10, 2026 7:31 AM - Globe NewsWire
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
March 9, 2026 5:16 PM - Globe NewsWire
Form 10-K SAB Biotherapeutics, For: Dec 31
March 9, 2026 5:11 PM - SEC Filing
Full Article List
